13208-44-1 Usage
Uses
Used in Chemical Research:
1-(3-chlorophenyl)-3-(4-fluorophenyl)urea is used as a research compound for studying its chemical properties and potential interactions with biological systems.
Used in Pharmaceutical Development:
In the pharmaceutical industry, 1-(3-chlorophenyl)-3-(4-fluorophenyl)urea is used as a lead compound for the development of new drugs. Its structure may be optimized to target specific enzymes or receptors, potentially leading to the creation of novel therapeutic agents.
Used in Medicinal Chemistry:
1-(3-chlorophenyl)-3-(4-fluorophenyl)urea is utilized as a chemical probe to investigate the mechanisms of action of certain biological targets. It may serve as an inhibitor, providing insights into the role of these targets in disease processes and the design of more effective drugs.
Safety Considerations:
Due to its potential hazards if not handled properly, 1-(3-chlorophenyl)-3-(4-fluorophenyl)urea requires careful handling and storage to ensure the safety of researchers and the environment. Proper safety protocols should be followed during its use in laboratories and industrial settings.
Check Digit Verification of cas no
The CAS Registry Mumber 13208-44-1 includes 8 digits separated into 3 groups by hyphens. The first part of the number,starting from the left, has 5 digits, 1,3,2,0 and 8 respectively; the second part has 2 digits, 4 and 4 respectively.
Calculate Digit Verification of CAS Registry Number 13208-44:
(7*1)+(6*3)+(5*2)+(4*0)+(3*8)+(2*4)+(1*4)=71
71 % 10 = 1
So 13208-44-1 is a valid CAS Registry Number.
13208-44-1Relevant academic research and scientific papers
COMPOSITIONS AND METHODS FOR THE TREATMENT OF CANCER
-
, (2020/07/08)
This disclosure relates to compounds, pharmaceutical compositions comprising them, and methods of using the compounds and compositions for treating diseases related to Heat Shock Transcription Factor 1 (HSF1) activity and/or function. More particularly, this disclosure relates to methods of inhibiting HSF1 activity with these compounds and pharmaceutical compositions thereof, and methods of treating diseases associated with HSF1 activity and/or function, such as cancer.
Evaluation of diarylureas for activity against plasmodium falciparum
Zhang, Yiqun,Anderson, Marc,Weisman, Jennifer L.,Lu, Min,Choy, Cindy J.,Boyd, Vincent A.,Price, Jeanine,Sigal, Martina,Clark, Julie,Connelly, Michele,Zhu, Fangyi,Guiguemde, W. Armand,Jeffries, Cynthia,Yang, Lei,Lemoff, Andrew,Liou, Ally P.,Webb, Thomas R.,Derisi, Joseph L.,Guy, R. Kiplin
scheme or table, p. 460 - 465 (2011/02/27)
A library of diarylurea insulin-like growth factor 1 receptor inhibitors was screened for activity against chloroquine-sensitive (3D7) and chloroquine-resistant (K1) strains of Plasmodium falciparum. The 4-aminoquinaldine-derived diarylureas displayed pro
